Control of drooling with transdermal scopolamine in a child with cerebral palsy

Area of Science:

• Neurology
• Pharmacology
• Pediatrics

Background:

• Cerebral palsy (CP) often involves motor impairments, including spastic quadriplegia, which can lead to significant drooling (sialorrhea).
• Severe drooling in children with CP can cause secondary complications such as respiratory distress and increased risk of aspiration.
• Current management strategies for sialorrhea in CP may have limitations or side effects.

Observation:

• A two-year-old boy diagnosed with severe spastic quadriparetic cerebral palsy and developmental delay presented with problematic drooling.
• Continuous transdermal scopolamine patch therapy (1.5 mg) was initiated to manage the patient's excessive salivation.

Findings:

• The transdermal scopolamine therapy resulted in a marked reduction in drooling.
• Secondary benefits included a decrease in respiratory distress and a reduced frequency of required suctioning.
• No significant adverse effects were observed during the treatment period.

Implications:

• Transdermal scopolamine patches represent a viable and effective treatment option for managing sialorrhea in pediatric patients with severe cerebral palsy.
• This therapeutic approach may improve quality of life by mitigating secondary complications associated with excessive drooling.
• Further research into the long-term efficacy and safety of transdermal scopolamine for pediatric sialorrhea is warranted.